Clinical trial of MK-2870 in people with non-small cell lung cancer

• Research type

  Research Study

• Full title

  A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations

• IRAS ID

  1008276

• Contact name

  - -

• Contact email

  N/A

• Sponsor organisation

  Merck Sharp & Dohme LLC

• Research summary

  This trial is testing MK-2870 in people with Non-squamous Non-small Cell Lung Cancer (NSCLC) that cannot be treated with surgery or radiation or that has spread to other parts of the body; also called advanced or metastatic NSCLC.
  MK-2870 is a drug that targets markers on the surface of tumour cells and causes tumour cells to die by preventing their growth.
  MK-2870 is experimental. It is not approved to treat any type of cancer. The trial will compare MK-2870 to docetaxel and pemetrexed, which are standard chemotherapies used to treat advanced or metastatic NSCLC. Approximately 556 people aged 18 years and over will take part.
  There is a screening phase lasting about a month to see if participants can be in the trial. Eligible participants will then be randomly placed in a 1:1 ratio into one of 2 groups.
  • Group 1 – receive MK-2870 about every 2 weeks via an intravenous (IV) infusion (needle in a vein)
  • Group 2 – receive docetaxel or pemetrexed about every 3 weeks via an IV infusion.
  The participant and trial doctor will know what treatment is given.
  All participants will have a physical exam, provide urine & tumour samples, undergo tumour scans, bone scans and ECGs. Blood tests (including genetic blood analysis) will monitor participants progress and safety throughout the trial.
  Participants will continue treatment as long as their cancer does not get worse, they tolerate treatment and they do not start a new cancer treatment. After treatment stops, participants will enter the follow up phase and be contacted about every 3 months to check on their health. Participants will be in the trial for about 6 years. The duration of the trial will be approximately 6 years.
  The trial is sponsored by Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc. (MSD).

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  23/LO/0822

• Date of REC Opinion

  20 Dec 2023

• REC opinion

  Further Information Favourable Opinion